

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/591,371
		Filing Date	09/01/2006
		First Named Inventor	RUSSWURM
		Art Unit	<del>xxxx</del> 1634 1625
		Examiner Name	<del>xxxxxx</del> ST Kapushoc Unassigned
Sheet 1	of 5	Attorney Docket Number 3535-022	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		ABRAHAM, et al., "Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A random...", Crit Care Med 29(3): 503-510 (2001).	
		ABRAHAM, et al., "Sepsis Therapy Trials: Continued Dissappointment or Reason to Hope?", JAMA, 271(23): 1876-1878 (1994).	
		ABRAHAM, et al., "Assessment of the safety recombinant tissue factor pathway inhibitor in patients with severe sepsis...", Crit Care Med, 29(11): 2081-2089 (2001).	
		ABRAHAM, et al., "Sepsis and mediator-directed therapy: rethinking the target populations", Molecular Medicine Today, 56-58 (1999).	
		ALBERTI, et al., "Influence of Systemic Inflammatory Response Syndrome and Sepsis on Outcome of Critically Ill Infected Patients", Am J Respir Crit Care Med, 168:77-84 (2003).	
		ALIZADEH, et al., "Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling", Nature, 403: 503-511 (2000).	
		BEUTLER, et al., "Sepsis and evolution of the innate immune response", Crit Care Med, 29(7) Suppl.: S2-S7 (2001).	
		BONE, et al., "The ACCP/SCCM Consensus Conference on Sepsis and Organ Failure", 101(6): 1481-1483 (1992).	
		BONE, ROGER C., "Sepsis, the Sepsis Syndrome, Multi-Organ Failure: A Plea for Comparable Definitions", Annals of Internal Medicine, 114(4): 332-3 (1991).	
		BONE, ROGER C., "The Pathogenesis of Sepsis", Annals of Internal Medicine, 115: 457-469 (1991).	

Examiner Signature	/Stephen Kapushoc/	Date Considered	02/25/2010
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /STK/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/591,371
		Filing Date	09/01/2006
		First Named Inventor	RUSSWURM
		Art Unit	<del>1623</del> 1634
		Examiner Name	Unassigned ST Kapushoc
Sheet 2 of 5	Attorney Docket Number	3535-022	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		BRUN-BUISSON, et al., "Incidence, Risk Factors, and Outcome of Severe Sepsis and Septic Shock in Adults", JAMA 274(12): 968-974 (1995).	
		BRUN-BUISSON, et al., "The costs of septic syndromes in the intensive care unit and influence of hospital-acquired sepsis", Intensive Care Med, 29: 1464-1471 (2003).	
		EILING, et al., "Identification of differentially expressed genes during systemic inflammatory response syndrome using cDNA microarrays", Infection, 31: 301 (2003).	
		FILLION, et al., "Role of Chemokines and Formyl Peptides in Pneumococcal Pneumonia-Induced Monocyte/Macrophage Recruitment", Journal of Immunology, 166: 7353-7361 (2001).	
		FODOR, et al., "Light-Directed, Spatially Addressable Parallel Chemical Synthesis", Science, 215: 767-773 (1991).	
		FRIEDLAND, et al., "Plasma proinflammatory cytokine concentrations, Acute Physiology and Chronic Health Evaluation (APACHE)...", Crit Care Med, 24(11): 1775-1781 (1996).	
		GILLESPIE, et al., "A Quantitative Assay for DNA-RNA Hybrids with DNA immobilized on a Membrane", J. Mol. Biol., 12: 829-842 (1965).	
		GOLUB, et al., "Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring", Science, 286: 531-537 (1999).	
		HENRY, et al., "Chipping away at brain function: mining for insights with microarrays", Current Opinion in Neurobiology, 13: 570-576 (2003).	
		HUBER, et al., "Parameter estimation for the calibration and variance stabilization...", Statistical Applications in Genetics and Molecular Biology, 2(1): 1-22 (2003).	

Examiner Signature	/Stephen Kapushoc/	Date Considered	02/25/2010
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /STK/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/591,371
		Filing Date	09/01/2006
		First Named Inventor	RUSSWURM
		Art Unit	<del>1625</del> 1634
		Examiner Name	<del>Unassigned</del> ST Kapushoc
Sheet 3 of 5	Attorney Docket Number	3535-022	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		"Increase in National Hospital Discharge Survey Rates for Septicemia--United States, 1979-1987", MMWR Morb Mortal Wkly Rep, 39(2): 31-34 (1990).	
		KAFATOS, et al., "Determination of nucleic acid sequence homologies and relative concentrations by a dot hybridization...", Nucelic Acids Research, 7(6): 1541-1552 (1979).	
		LE GALL, et al., "Customized Probability Models for Early Severe Sepsis in Adult Intensive Care Patients", JAMA, 273(8): 644-650 (1995).	
		LENNON, et al., "Hybridization analyses of arrayed cDNA libraries", Trends Genet, 7(10): 314-317 (1991).	
		LEVY, et al., "2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference", Crit Care Med, 31(4): 1250-1256 (2003).	
		MARSHALL, et al., "SIRS AND MODS: WHAT IS THEIR RELEVANCE TO THE SCIENCE AND PRACTICE OF INTENSIVE CARE?", Shock, 14(6): 586-589 (2000).	
		MARSHALL, et al., "Measures, markers and mediators: Toward a staging system for clinical sepsis. A Report of the Fifth Toronto Sepsis...", Crit Care Med, 31(5): 1560-67 (2003).	
		MATOT, et al., "Definition of sepsis", Intensive Care Med, 27:S3-S9 (2001).	
		PATHAN, et al., "Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock", Lancet, 363: 203-209 (2004).	
		PEASE, et al., "Light-generated oligonucleotide arrays for rapid DNA sequence analysis", Proc. Natl. Acad. Sci., 91: 5022-5026 (1994).	

Examiner Signature	/Stephen Kapushoc/	Date Considered	02/25/2010
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /STK/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/591,371
		Filing Date	09/01/2006
		First Named Inventor	RUSSWURM
		Art Unit	<del>1623</del> 1634
		Examiner Name	<del>Unassigned</del> ST Kapushoc
Sheet 4 of 5	Attorney Docket Number	3535-022	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		PITTET, et al., "Impact of Immunomodulating Therapy on Morbidity in Patients with Severe Sepsis", Am J Respir Crit Care Med 160: 852-857 (1999).	
		POEZE, et al., "An international sepsis survey: a study of doctors' knowledge and perception about sepsis", Critical Care, 8(6): R409-R413, 1-6 (2004).	
		RUSSWURM, et al., "PROCALCITONIN AS MONOCYTE MARKER FOR EARLY DIAGNOSIS OF SEPTIC ABORTION", Z Geburtsh Neonatol, 204: 34-38 (2000).	
		RUSSWURM, S., "Procalcitonin as a Marker of Bacterial Infections and Sepsis: Effect of Sepsis-Relevant Conditions on the Expression of Procalcitonin", 1-44 (2002).	
		SCHENA, et al., "Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray", Science, 270: 467-469 (1995).	
		SOUTHERN, E.M., "An Improved Method for Transferring Nucleotides from Electrophoresis Strips to Thin Layers of Ion-Exchange..." Analytical Biochemistry, 62: 317-8 (1974).	
		STRAUBE, E., "Sepsis - microbiological diagnosis", Infection, 31(4): 284-5 (2003).	
		VINCENT, J., "Dear SIRS, I'm sorry to say that I don't like you...", Crit Care Med, 25(2): 372-374 (1997).	
		VINCENT, et al., "Clinical expert round table discussion (session 5) at the Margaux Conference on Critical Illness...", Crit Care Med, 29(7) Suppl.: S136-S137 (2001).	
		ZENI, et al., "Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment", Crit Care Med, 25(7): 1095-1100 (1997).	

Examiner Signature	/Stephen Kapushoc/	Date Considered	02/25/2010
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /STK/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/591,371
		Filing Date	09/01/2006
		First Named Inventor	RUSSWURM
		Art Unit	<del>1628</del> 1634
		Examiner Name	<del>Unassigned</del> ST Kapushoc
Sheet 5	of 5	Attorney Docket Number 3535-022	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		ZHAO, et al., "Human endothelial cell reponse to gram-negative lipopolysaccharide assessed with cDNA microarrays", Am J Physiol Cell Physiol, 281: C1587-C1595 (2001).	

Examiner Signature	/Stephen Kapushoc/	Date Considered	02/25/2010
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /STK/